Shares of Boston Scientific fell sharply on Monday, declining around 9% after investors reacted cautiously to results from its closely watched CHAMPION AF clinical trial.

Boston Scientific announced on Thursday that it will acquire Penumbra in a deal valued at approximately $14.5 billion, aiming to expand its vascular product pipeline.